Vested interests are redefining, rebranding and co-opting what is 'biopharmaceutical'. This is not just a matter of semantics—the core identity of the biotech industry and its products is at stake.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Histidine-based ionizable cationic surfactants: novel biodegradable agents for hydrophilic macromolecular drug delivery
Drug Delivery and Translational Research Open Access 30 January 2024
-
Digital Double Diamond (DiDD) Model Analysis of National Competitiveness Under Digital Transformation: An Application to Healthcare and Pharmaceutical Industries in South Korea and Switzerland
International Journal of Global Business and Competitiveness Open Access 10 July 2023
-
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Journal of Cancer Research and Clinical Oncology Open Access 17 April 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rader, R.A. Biopharmaceutical Products in the US and European Markets, 6th ed., 2 vols., (BioPlan Associates, Rockville, MD, 2007). <http://www.biopharma.com/>
Rader, R.A. BioExecutive Intl., March, 60–65 (2005). <http://www.biopharma.com/BioExec_pt1.pdf>
Rader, R.A. BioExecutive Intl., May, 42–49 (2005). <http://www.biopharma.com/BioExec_pt2.pdf>
Walsh, G. & Jefferis, R. Nat. Biotechnol. 24, 1241–1252 (2006).
Akers, M.J. BioProcess Intl. 4, 36–43 (2006).
Webster, C. et al. BioPharm Intl. July, 1 (2003).
Copmann, T. et al. BioPharm Intl. March, 14–24 (2001).
Scott, C. BioProcess Intl. 3, 80 (2005). <http://www.bioprocessintl.com/default.asp?page=article_display&docid=61200511&display=full/>
Walsh, G. Eur. J. Pharm. Sci. 15, 135–138 (2002).
Eby, R.J. et al. The Story of Prevnar (Pharmaceutical Research and Manufacturers Association, Washington, DC, 2008). <http://www.innovation.org/index.cfm/StoriesofInnovation/Â InnovatorStories/The_Story_of_Prevnar/>
Ernst & Young . Beyond Borders: Ernst & Young Global Biotechnology Report 2007 (Ernst & Young, New York, 2007).
DeVol, R. et al. Biopharmaceutical Industry Contributions to State and US Economics (Milken Institute, Santa Monica, CA, USA, 2004). <http://www.milkeninstitute.org/pdf/biopharma_report.pdf>
Ernst & Young . Convergence: Ernst & Young's Biotechnology Industry Report, Millennium Edition (Ernst & Young, New York, 2000).
PhRMA. Introduction, 2005 Industry Profile (PhRMA, Washington, DC, 2006). <http://members.phrma.org/publications/publications//2005-03-17.1144.pdf>
PhRMA. Annual Report 2006–2007: Biopharmaceutical Inspiration, (PhRMA, Washington, DC, 2007). <http://www.phrma.org/files/Annual_Report_2006_2007.pdf>
Myshko, D. PharmaVOICE, October, 40–44 (2006).
Frantz, S. Nat. Rev. Drug Discov. 5, 977–979 (2006).
Simons, J. Fortune, 28 February 2006. <http://money.cnn.com/2006/02/27/news/companies/Â pluggedin_fortune/index.htm/>
Anonymous. Seeking Alpha. 9 January 2007. <http://seekingalpha.com/article/23696-the-biotech-industry-30-years-of-failure-starting-with-genentech/>
Chase, M. The Wall Street Journal, p. B1 (June 5, 2007). <http://online.wsj.com/public/article/SB118100806142024548-PFa4u2AiKfDHi25uT1jvHmdJZKA_20070612.html?mod=blogs>
Schoemaker, P. & Tomczyk, M.S. BioProcess Intl. 4, 64 (2006).
Rader, R.A. US BIOPHARMACOPEIA Registry of Biopharmaceutical Products (Biotechnology Information Institute, Rockville, MD, USA, 2007). <http://www.biopharmacopeia.com/>
German Association of Research-Based Pharmaceutical Companies (VFA). Biological/Biotechnological Generics Cannot Exist (VFA, Berlin, Germany, July 25, 2006). <http://www.vfa.de/vfa-bio_en/vb_press/vb_positionen_en/biosimilars.html>
Miller, H.I. Trends Biotechnol. 5, 56–59 (2007).
Rader, R.A. BioProcess Intl. 5, 28–39 (March 2007). <http://www.biopharma.com/whatsabiogeneric_pt1.pdf>
Rader, R.A. BioProcess Intl. 5, 20–27 (May 2007). <http://www.biopharma.com/whatsabiogeneric_pt2.pdf>
Katz, K.A. Br. J. Dermatol. 154, 809–812 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rader, R. (Re)defining biopharmaceutical. Nat Biotechnol 26, 743–751 (2008). https://doi.org/10.1038/nbt0708-743
Issue Date:
DOI: https://doi.org/10.1038/nbt0708-743
This article is cited by
-
Histidine-based ionizable cationic surfactants: novel biodegradable agents for hydrophilic macromolecular drug delivery
Drug Delivery and Translational Research (2024)
-
Digital Double Diamond (DiDD) Model Analysis of National Competitiveness Under Digital Transformation: An Application to Healthcare and Pharmaceutical Industries in South Korea and Switzerland
International Journal of Global Business and Competitiveness (2023)
-
Enzyme Engineering Strategies for the Bioenhancement of l-Asparaginase Used as a Biopharmaceutical
BioDrugs (2023)
-
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Journal of Cancer Research and Clinical Oncology (2022)
-
Biosimilars – Chancen und Risiken
Der Internist (2020)